Clinical Implications of Six-minute Walk Test in Patients with Idiopathic Pulmonary Fibrosis: a Retrospective Cohort Study

Overview

Journal Ther Adv Respir Dis

Publisher Sage Publications

Specialties Pharmacology
Pulmonary Medicine

Date 2024 Aug 23

PMID 39175212

Authors

Min Jee Kim

Steven D Nathan

Hyeon Hwa Kim

Ho Cheol Kim

Affiliations

Soon will be listed here.

Abstract

Background: A six-minute walk test (6MWT) is a reproducible, easily performed test, and is widely used to determine functional exercise capacity in patients with idiopathic pulmonary fibrosis (IPF). However, there is currently a paucity of data on the clinical significance of baseline and serial 6-minute walk tests in patients with IPF, especially in Asian patients.

Objectives: We aimed to investigate the clinical significance of serial 6MWT in patients with IPF, especially in Asian patients.

Design: This is a single-center retrospective cohort study.

Methods: Clinical data of patients diagnosed with IPF at a tertiary center in Korea were retrospectively analyzed. IPF diagnosis was defined according to the clinical guidelines of the American Thoracic Society (ATS)/European Respiratory Society (ERS)/Japanese Respiratory Society/Latin American Thoracic Association.

Results: There were 216 patients diagnosed with IPF from December 2012 to January 2022, of whom 198 had a baseline of 6MWT data. The mean age of the cohort was 66.9 ± 8.6, and 89% were male. The non-survivors showed significantly lower six-minute walk distance (6MWD), minimum saturation of peripheral oxygen (SpO) during 6MWT, forced vital capacity, and diffusing capacity of the lung for carbon monoxide than survivors at baseline. A multivariate Cox analysis demonstrated that lower minimum SpO was independently associated with increased mortality rates (Hazard ratio (HR): 1.081, 95% confidence interval (CI): 1.024-1.142, = 0.005). Higher mortality rates were also associated with echocardiographic-determined pulmonary hypertension (HR: 2.466, 95% CI: 1.149-5.296, = 0.021) at diagnosis. Among 144 patients with 6MWT results at 12 months, patients with a decline of 50 m or more in the 6MWD showed poorer overall survival than others (median survival: 45.0 months vs 58.0 months, < 0.001).

Conclusions: Baseline lower minimum SpO during 6MWT was an independent prognostic factor in patients with IPF, and a decline in 6MWD in serial follow-up was also associated with a poorer prognosis. These findings suggest that both baseline 6MWT and follow-up data are important in the prognostication of patients with IPF.

References

Wanger J, Clausen J, Coates A, Pedersen O, Brusasco V, Burgos F . Standardisation of the measurement of lung volumes. Eur Respir J. 2005; 26(3):511-22. DOI: 10.1183/09031936.05.00035005. View

Lettieri C, Nathan S, Browning R, Barnett S, Ahmad S, Shorr A . The distance-saturation product predicts mortality in idiopathic pulmonary fibrosis. Respir Med. 2006; 100(10):1734-41. DOI: 10.1016/j.rmed.2006.02.004. View

Tonelli A, Sahay S, Gordon K, Edwards L, Allmon A, Broderick M . Impact of inhaled treprostinil on risk stratification with noninvasive parameters: a post hoc analysis of the TRIUMPH and BEAT studies. Pulm Circ. 2021; 10(4):2045894020977025. PMC: 7739096. DOI: 10.1177/2045894020977025. View

Richeldi L, du Bois R, Raghu G, Azuma A, Brown K, Costabel U . Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370(22):2071-82. DOI: 10.1056/NEJMoa1402584. View

Caminati A, Bianchi A, Cassandro R, Mirenda M, Harari S . Walking distance on 6-MWT is a prognostic factor in idiopathic pulmonary fibrosis. Respir Med. 2008; 103(1):117-23. DOI: 10.1016/j.rmed.2008.07.022. View

Raghu G, Rochwerg B, Zhang Y, Garcia C, Azuma A, Behr J . An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med. 2015; 192(2):e3-19. DOI: 10.1164/rccm.201506-1063ST. View

Alkukhun L, Wang X, Ahmed M, Baumgartner M, Budev M, Dweik R . Non-invasive screening for pulmonary hypertension in idiopathic pulmonary fibrosis. Respir Med. 2016; 117:65-72. PMC: 4976395. DOI: 10.1016/j.rmed.2016.06.001. View

Holland A, Spruit M, Troosters T, Puhan M, Pepin V, Saey D . An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J. 2014; 44(6):1428-46. DOI: 10.1183/09031936.00150314. View

Brown A, Nathan S . The Value and Application of the 6-Minute-Walk Test in Idiopathic Pulmonary Fibrosis. Ann Am Thorac Soc. 2017; 15(1):3-10. DOI: 10.1513/AnnalsATS.201703-244FR. View

10.

Nathan S, Waxman A, Rajagopal S, Case A, Johri S, Dubrock H . Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study. Lancet Respir Med. 2021; 9(11):1266-1274. DOI: 10.1016/S2213-2600(21)00165-X. View

11.

Waxman A, Restrepo-Jaramillo R, Thenappan T, Ravichandran A, Engel P, Bajwa A . Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease. N Engl J Med. 2021; 384(4):325-334. DOI: 10.1056/NEJMoa2008470. View

12.

Behr J, Prasse A, Wirtz H, Koschel D, Pittrow D, Held M . Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry. Eur Respir J. 2020; 56(2). DOI: 10.1183/13993003.02279-2019. View

13.

King Jr T, Bradford W, Castro-Bernardini S, Fagan E, Glaspole I, Glassberg M . A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370(22):2083-92. DOI: 10.1056/NEJMoa1402582. View

14.

Nathan S, Barbera J, Gaine S, Harari S, Martinez F, Olschewski H . Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J. 2018; 53(1). PMC: 6351338. DOI: 10.1183/13993003.01914-2018. View

15.

MacIntyre N, Crapo R, Viegi G, Johnson D, van der Grinten C, Brusasco V . Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J. 2005; 26(4):720-35. DOI: 10.1183/09031936.05.00034905. View

16.

Nathan S, du Bois R, Albera C, Bradford W, Costabel U, Kartashov A . Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis. Respir Med. 2015; 109(7):914-22. DOI: 10.1016/j.rmed.2015.04.008. View

17.

Lee S, Kim S, Kim D, Kim Y, Chung M, Uh S . Predicting survival of patients with idiopathic pulmonary fibrosis using GAP score: a nationwide cohort study. Respir Res. 2016; 17(1):131. PMC: 5069824. DOI: 10.1186/s12931-016-0454-0. View

18.

von Elm E, Altman D, Egger M, Pocock S, Gotzsche P, Vandenbroucke J . The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007; 147(8):573-7. DOI: 10.7326/0003-4819-147-8-200710160-00010. View

19.

de Andrade J, Neely M, Hellkamp A, Culver D, Kim H, Liesching T . Effect of Antifibrotic Therapy on Survival in Patients With Idiopathic Pulmonary Fibrosis. Clin Ther. 2023; 45(4):306-315. DOI: 10.1016/j.clinthera.2023.03.003. View

20.

Miller M, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A . Standardisation of spirometry. Eur Respir J. 2005; 26(2):319-38. DOI: 10.1183/09031936.05.00034805. View